Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
BI 1356225 in Opioid Use Disorder
NCT06628622Phase 1Terminated
- Sponsor
- Boehringer Ingelheim
- Start
- Jan 2025
- Primary completion
- Mar 2026
- Modality
- Small Molecules
- Countries
- 1
01
Overview
Phase 1, randomised, double-blind trial in opioid use disorder (OUD) comparing BI 1356225 with Placebo (2 arms). Primary endpoint: Change from baseline in k parameter of the delay discounting task at Day 8. Started Jan 2025; status: terminated.
02
Drugs
BI 1356225
03
Conditions
opioid use disorder (OUD)
Beyond the preview
Go deeper on NCT06628622.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT06628622.